View ValuationMacrogen 将来の成長Future 基準チェック /46Macrogen利益と収益がそれぞれ年間89%と19.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に13.7% 88.9%なると予測されています。主要情報89.0%収益成長率88.87%EPS成長率Life Sciences 収益成長24.4%収益成長率19.1%将来の株主資本利益率13.70%アナリストカバレッジLow最終更新日30 Jan 2026今後の成長に関する最新情報Major Estimate Revision • Mar 30Consensus EPS estimates increase by 30%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩151.0m to ₩158.0m. EPS estimate increased from ₩819 to ₩1,065 per share. Net income forecast to grow 398% next year vs 36% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩30,000 unchanged from last update. Share price rose 3.5% to ₩20,300 over the past week.Price Target Changed • Oct 14Price target decreased to ₩30,000Down from ₩40,000, the current price target is provided by 1 analyst. New target price is 68% above last closing price of ₩17,850. Stock is down 39% over the past year. The company is forecast to post earnings per share of ₩859 for next year compared to ₩114 last year.すべての更新を表示Recent updatesNew Risk • May 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩148.2b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩148.2b market cap, or US$98.4m).分析記事 • Apr 03There May Be Underlying Issues With The Quality Of Macrogen's (KOSDAQ:038290) EarningsMacrogen, Inc. ( KOSDAQ:038290 ) announced strong profits, but the stock was stagnant. We did some digging, and we...お知らせ • Feb 26Macrogen, Inc., Annual General Meeting, Mar 31, 2026Macrogen, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 238, teheran-ro, gangnam-gu, seoul South Korea分析記事 • Dec 22Fewer Investors Than Expected Jumping On Macrogen, Inc. (KOSDAQ:038290)You may think that with a price-to-sales (or "P/S") ratio of 1.1x Macrogen, Inc. ( KOSDAQ:038290 ) is definitely a...Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 23 April 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (12%).分析記事 • Nov 09Macrogen's (KOSDAQ:038290) Dividend Will Be ₩300.00Macrogen, Inc. ( KOSDAQ:038290 ) has announced that it will pay a dividend of ₩300.00 per share on the 23rd of April...Declared Dividend • Nov 08Dividend of ₩300 announcedDividend of ₩300 is the same as last year. Ex-date: 29th December 2025 Payment date: 23rd April 2026 Dividend yield will be 2.0%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 5 years but payments have been stable during that time.お知らせ • Nov 07Macrogen, Inc. announces Annual dividend, payable on April 23, 2026Macrogen, Inc. announced Annual dividend of KRW 300.0000 per share payable on April 23, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.分析記事 • Mar 19Calculating The Intrinsic Value Of Macrogen, Inc. (KOSDAQ:038290)Key Insights The projected fair value for Macrogen is ₩15,809 based on 2 Stage Free Cash Flow to Equity Current share...お知らせ • Feb 27Macrogen, Inc., Annual General Meeting, Mar 31, 2025Macrogen, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 238, teheran-ro, gangnam-gu, seoul South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 25 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.0%).お知らせ • Dec 11Macrogen, Inc. (KOSDAQ:A038290) agreed to acquire an additional 17.44% stake in Psomagen, Inc. (KOSDAQ:A950200) for KRW 13.5 billion.Macrogen, Inc. (KOSDAQ:A038290) agreed to acquire an additional 17.44% stake in Psomagen, Inc. (KOSDAQ:A950200) for KRW 13.5 billion on December 9, 2024. A cash consideration of KRW 13.54 billion will be paid by Macrogen for 3,355,338 shares. Upon completion, Macrogen, Inc. will own 54.25% stake in Psomagen, Inc. The expected completion of the transaction is December 26, 2024.New Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.分析記事 • Nov 13Macrogen, Inc.'s (KOSDAQ:038290) Low P/S No Reason For ExcitementMacrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong buy right...分析記事 • Jul 24Macrogen, Inc.'s (KOSDAQ:038290) Revenues Are Not Doing Enough For Some InvestorsMacrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a strong buy right...New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change).Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per share at 1.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.9%).New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change).New Risk • Oct 10New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 61% per year over the past 5 years.Buying Opportunity • Jul 10Now 21% undervaluedOver the last 90 days, the stock is up 5.9%. The fair value is estimated to be ₩28,610, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.New Risk • Jun 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).Buying Opportunity • Apr 10Now 20% undervaluedOver the last 90 days, the stock is up 2.7%. The fair value is estimated to be ₩26,056, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.Major Estimate Revision • Mar 30Consensus EPS estimates increase by 30%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩151.0m to ₩158.0m. EPS estimate increased from ₩819 to ₩1,065 per share. Net income forecast to grow 398% next year vs 36% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩30,000 unchanged from last update. Share price rose 3.5% to ₩20,300 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Oct 22Macrogen, Inc. (KOSDAQ:A038290) announces an Equity Buyback for KRW 3,000 million worth of its shares.Macrogen, Inc. (KOSDAQ:A038290) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a trust contract with Samsung Securities Co., Ltd. The purpose of the share repurchase program is to stabilize the share price and increase shareholders value. The share repurchase program will continue until October 20, 2023. As of October 20, 2022, the company had 722,395 shares in treasury within scope available for dividend and had 1,851 shares in treasury through other repurchase.Price Target Changed • Oct 14Price target decreased to ₩30,000Down from ₩40,000, the current price target is provided by 1 analyst. New target price is 68% above last closing price of ₩17,850. Stock is down 39% over the past year. The company is forecast to post earnings per share of ₩859 for next year compared to ₩114 last year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 25 April 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.3%).分析記事 • Apr 02Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsThe subdued market reaction suggests that Macrogen, Inc.'s ( KOSDAQ:038290 ) recent earnings didn't contain any...分析記事 • Mar 03Macrogen (KOSDAQ:038290) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 18New 90-day high: ₩30,650The company is up 8.0% from its price of ₩28,400 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 2.0% over the same period.Is New 90 Day High Low • Jan 18New 90-day low: ₩25,450The company is down 12% from its price of ₩28,800 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.分析記事 • Jan 09Reflecting on Macrogen's (KOSDAQ:038290) Share Price Returns Over The Last Three YearsFor many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...Is New 90 Day High Low • Dec 23New 90-day low: ₩25,800The company is down 14% from its price of ₩29,900 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 14% over the same period.Is New 90 Day High Low • Oct 15New 90-day low: ₩29,500The company is down 8.0% from its price of ₩31,900 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 1.0% over the same period.お知らせ • Sep 24Macrogen Signs Export Agreement with LG InternationalMacrogen has established the first "Smart Mobile Lab" in Korea and has supplied it to Indonesia as well. Macrogen signed its first export agreement with LG International, on September 22nd. The initial two export units will be supplied to Indonesia through LG International. Following the first agreement, additional units are currently in last-minute negotiation over additional export agreements. Macrogen's Smart Mobile Lab is the mobile container type for on-site COVID 19 testing developed in Korea. It offers one-stop COVID-19 testing within a matter of minutes and it can be easily installed wherever as necessary. Macrogen has designed the SML that is easy to move and install in order to supply the K-quarantine packaging to overseas that are suffering from COVID-19 testing because of insufficient healthcare quarantine infrastructure. SML with strict Bio Safety Level-2(BSL-2) deals with all stages from viral RNA extraction, real-time polymerase chain reaction (RT-PCR), diagnosis, analysis, and to results. It also provides unique and differentiated services for Standard Operating Procedures (SOP), online/on-site training for lab technicians, and instrument maintenance. Macrogen's SML also displays excellent performance in terms of sustainability as it can be extended into a process capable of molecular diagnostic testing for various infectious diseases other than COVID-19. Currently, Macrogen is in the course of preparation for related patent applications based on the unique design structure of SML and the implementation of differentiated additional features.業績と収益の成長予測KOSDAQ:A038290 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2027287,40024,10022,00039,700112/31/2026241,10011,10010,50013,600112/31/2025195,2682,030-13,72622,347N/A9/30/2025179,980-700-26,92416,097N/A6/30/2025163,919-6,339-32,9576,917N/A3/31/2025145,097-7,763-25,12511,123N/A12/31/2024135,777-7,603-28,3947,124N/A9/30/2024131,729-21,730-20,3799,431N/A6/30/2024131,018-20,526-20,0877,269N/A3/31/2024131,009-20,395-22,8226,895N/A12/31/2023132,803-16,814-19,5824,765N/A9/30/2023133,923-22,286-13,8796,858N/A6/30/2023137,180-18,778-11,7299,961N/A3/31/2023136,765-20,892-10,0189,504N/A12/31/2022138,617-22,253-9,01710,767N/A9/30/2022137,8502,257-11,1808,652N/A6/30/2022130,775872-4,5789,661N/A3/31/2022130,2684,2123,26014,207N/A12/31/2021129,1751,11211,30821,127N/A9/30/2021125,233-12,32122,79828,423N/A6/30/2021123,9621,29922,22031,255N/A3/31/2021118,03721314,10627,519N/A12/31/2020112,6034,2671,20420,553N/A9/30/202095,78719,627-23,83412,406N/A6/30/202098,4834,341-18,99612,977N/A3/31/2020101,85210,527-56,38517,073N/A12/31/2019102,81517,892-56,48914,496N/A9/30/2019120,20812,059N/A19,808N/A6/30/2019115,15012,488N/A17,279N/A3/31/2019115,6399,104N/A8,259N/A12/31/2018112,8312,645N/A15,607N/A9/30/2018108,57512,550N/A11,142N/A6/30/2018107,95913,228N/A12,401N/A3/31/2018104,46214,173N/A12,911N/A12/31/2017101,7939,529N/A13,067N/A9/30/201798,4721,661N/A9,372N/A6/30/201794,772-558N/A13,294N/A3/31/201792,3956N/A17,360N/A12/31/201691,1134,301N/A21,247N/A9/30/201688,2077,049N/A17,092N/A6/30/201690,66311,895N/A13,535N/A3/31/201687,03011,508N/A7,985N/A12/31/201579,53410,172N/A7,155N/A9/30/201573,9264,746N/A6,998N/A6/30/201563,1162,812N/A3,607N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A038290の予測収益成長率 (年間89% ) は 貯蓄率 ( 3.1% ) を上回っています。収益対市場: A038290の収益 ( 89% ) はKR市場 ( 31.2% ) よりも速いペースで成長すると予測されています。高成長収益: A038290の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: A038290の収益 ( 19.1% ) KR市場 ( 15.5% ) よりも速いペースで成長すると予測されています。高い収益成長: A038290の収益 ( 19.1% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A038290の 自己資本利益率 は、3年後には低くなると予測されています ( 13.7 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 08:44終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Macrogen, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Song-hyup HanDaishin Securities Co. Ltd.Sang-Hun LeeiM SecuritiesJaehoon ChoiKorea Investment & Securities Co., Ltd.2 その他のアナリストを表示
Major Estimate Revision • Mar 30Consensus EPS estimates increase by 30%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩151.0m to ₩158.0m. EPS estimate increased from ₩819 to ₩1,065 per share. Net income forecast to grow 398% next year vs 36% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩30,000 unchanged from last update. Share price rose 3.5% to ₩20,300 over the past week.
Price Target Changed • Oct 14Price target decreased to ₩30,000Down from ₩40,000, the current price target is provided by 1 analyst. New target price is 68% above last closing price of ₩17,850. Stock is down 39% over the past year. The company is forecast to post earnings per share of ₩859 for next year compared to ₩114 last year.
New Risk • May 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩148.2b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩148.2b market cap, or US$98.4m).
分析記事 • Apr 03There May Be Underlying Issues With The Quality Of Macrogen's (KOSDAQ:038290) EarningsMacrogen, Inc. ( KOSDAQ:038290 ) announced strong profits, but the stock was stagnant. We did some digging, and we...
お知らせ • Feb 26Macrogen, Inc., Annual General Meeting, Mar 31, 2026Macrogen, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 238, teheran-ro, gangnam-gu, seoul South Korea
分析記事 • Dec 22Fewer Investors Than Expected Jumping On Macrogen, Inc. (KOSDAQ:038290)You may think that with a price-to-sales (or "P/S") ratio of 1.1x Macrogen, Inc. ( KOSDAQ:038290 ) is definitely a...
Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 23 April 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (12%).
分析記事 • Nov 09Macrogen's (KOSDAQ:038290) Dividend Will Be ₩300.00Macrogen, Inc. ( KOSDAQ:038290 ) has announced that it will pay a dividend of ₩300.00 per share on the 23rd of April...
Declared Dividend • Nov 08Dividend of ₩300 announcedDividend of ₩300 is the same as last year. Ex-date: 29th December 2025 Payment date: 23rd April 2026 Dividend yield will be 2.0%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 5 years but payments have been stable during that time.
お知らせ • Nov 07Macrogen, Inc. announces Annual dividend, payable on April 23, 2026Macrogen, Inc. announced Annual dividend of KRW 300.0000 per share payable on April 23, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
分析記事 • Mar 19Calculating The Intrinsic Value Of Macrogen, Inc. (KOSDAQ:038290)Key Insights The projected fair value for Macrogen is ₩15,809 based on 2 Stage Free Cash Flow to Equity Current share...
お知らせ • Feb 27Macrogen, Inc., Annual General Meeting, Mar 31, 2025Macrogen, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 238, teheran-ro, gangnam-gu, seoul South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 25 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.0%).
お知らせ • Dec 11Macrogen, Inc. (KOSDAQ:A038290) agreed to acquire an additional 17.44% stake in Psomagen, Inc. (KOSDAQ:A950200) for KRW 13.5 billion.Macrogen, Inc. (KOSDAQ:A038290) agreed to acquire an additional 17.44% stake in Psomagen, Inc. (KOSDAQ:A950200) for KRW 13.5 billion on December 9, 2024. A cash consideration of KRW 13.54 billion will be paid by Macrogen for 3,355,338 shares. Upon completion, Macrogen, Inc. will own 54.25% stake in Psomagen, Inc. The expected completion of the transaction is December 26, 2024.
New Risk • Dec 08New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.
分析記事 • Nov 13Macrogen, Inc.'s (KOSDAQ:038290) Low P/S No Reason For ExcitementMacrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong buy right...
分析記事 • Jul 24Macrogen, Inc.'s (KOSDAQ:038290) Revenues Are Not Doing Enough For Some InvestorsMacrogen, Inc.'s ( KOSDAQ:038290 ) price-to-sales (or "P/S") ratio of 1.8x might make it look like a strong buy right...
New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change).
Upcoming Dividend • Dec 20Upcoming dividend of ₩300 per share at 1.4% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.9%).
New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change).
New Risk • Oct 10New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 61% per year over the past 5 years.
Buying Opportunity • Jul 10Now 21% undervaluedOver the last 90 days, the stock is up 5.9%. The fair value is estimated to be ₩28,610, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Jun 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
Buying Opportunity • Apr 10Now 20% undervaluedOver the last 90 days, the stock is up 2.7%. The fair value is estimated to be ₩26,056, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
Major Estimate Revision • Mar 30Consensus EPS estimates increase by 30%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩151.0m to ₩158.0m. EPS estimate increased from ₩819 to ₩1,065 per share. Net income forecast to grow 398% next year vs 36% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩30,000 unchanged from last update. Share price rose 3.5% to ₩20,300 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (0.7%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Oct 22Macrogen, Inc. (KOSDAQ:A038290) announces an Equity Buyback for KRW 3,000 million worth of its shares.Macrogen, Inc. (KOSDAQ:A038290) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a trust contract with Samsung Securities Co., Ltd. The purpose of the share repurchase program is to stabilize the share price and increase shareholders value. The share repurchase program will continue until October 20, 2023. As of October 20, 2022, the company had 722,395 shares in treasury within scope available for dividend and had 1,851 shares in treasury through other repurchase.
Price Target Changed • Oct 14Price target decreased to ₩30,000Down from ₩40,000, the current price target is provided by 1 analyst. New target price is 68% above last closing price of ₩17,850. Stock is down 39% over the past year. The company is forecast to post earnings per share of ₩859 for next year compared to ₩114 last year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 25 April 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.3%).
分析記事 • Apr 02Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsThe subdued market reaction suggests that Macrogen, Inc.'s ( KOSDAQ:038290 ) recent earnings didn't contain any...
分析記事 • Mar 03Macrogen (KOSDAQ:038290) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 18New 90-day high: ₩30,650The company is up 8.0% from its price of ₩28,400 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Jan 18New 90-day low: ₩25,450The company is down 12% from its price of ₩28,800 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.
分析記事 • Jan 09Reflecting on Macrogen's (KOSDAQ:038290) Share Price Returns Over The Last Three YearsFor many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...
Is New 90 Day High Low • Dec 23New 90-day low: ₩25,800The company is down 14% from its price of ₩29,900 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 14% over the same period.
Is New 90 Day High Low • Oct 15New 90-day low: ₩29,500The company is down 8.0% from its price of ₩31,900 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 1.0% over the same period.
お知らせ • Sep 24Macrogen Signs Export Agreement with LG InternationalMacrogen has established the first "Smart Mobile Lab" in Korea and has supplied it to Indonesia as well. Macrogen signed its first export agreement with LG International, on September 22nd. The initial two export units will be supplied to Indonesia through LG International. Following the first agreement, additional units are currently in last-minute negotiation over additional export agreements. Macrogen's Smart Mobile Lab is the mobile container type for on-site COVID 19 testing developed in Korea. It offers one-stop COVID-19 testing within a matter of minutes and it can be easily installed wherever as necessary. Macrogen has designed the SML that is easy to move and install in order to supply the K-quarantine packaging to overseas that are suffering from COVID-19 testing because of insufficient healthcare quarantine infrastructure. SML with strict Bio Safety Level-2(BSL-2) deals with all stages from viral RNA extraction, real-time polymerase chain reaction (RT-PCR), diagnosis, analysis, and to results. It also provides unique and differentiated services for Standard Operating Procedures (SOP), online/on-site training for lab technicians, and instrument maintenance. Macrogen's SML also displays excellent performance in terms of sustainability as it can be extended into a process capable of molecular diagnostic testing for various infectious diseases other than COVID-19. Currently, Macrogen is in the course of preparation for related patent applications based on the unique design structure of SML and the implementation of differentiated additional features.